Piper Sandler raised the firm’s price target on CVS Health to $93 from $85 and keeps an Overweight rating on the shares. On Friday, CVS preannounced 2023 adjusted EPS in the upper half of the guidance range and reiterated 2024 GAAP and adjusted EPS floors, the firm says. Piper also notes that CVS is a top large cap pick, and that it would be a buyer of the stock at current levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CVS:
- Deutsche Bank maintains Hold on CVS Health after company update
- CVS Health to reaffirm FY23, FY24 EPS guidance at investor meeting
- CVS Health (NYSE:CVS) Affirms Strong Outlook amid Leadership Changes
- CVS Health appoints Tom Cowhey as CFO
- CVS Pharmacy announces two membership tiers for loyalty program
